Haw ParHAWPF 96 Return-on-Tangible-Equity is 5.79% as of Dec. 2025, which is 4% above its 10-year median of 5.58. GuruFocus rates HAWPF with a GF Score™ of 96/100 and a GF Value™ of $8.90. The stock has 3 warning signs investors should review. Among 895 Drug Manufacturers companies, Haw Par ranks worse than 54.64% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Haw Par's annualized net income for the quarter that ended in Dec. 2025 was $188.0 Mil. Haw Par's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $3,245.3 Mil. Therefore, Haw Par's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 5.79%.
The historical rank and industry rank for Haw Par's Return-on-Tangible-Equity or its related term are showing as below:
HAWPF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.63 Med: 5.58 Max: 6.38
Current: 6.38
During the past 13 years, Haw Par's highest Return-on-Tangible-Equity was 6.38%. The lowest was 3.63%. And the median was 5.58%.
HAWPF's Return-on-Tangible-Equity is ranked worse than 54.64% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs HAWPF: 6.38
Haw Par (OTCPK:HAWPF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Haw Par Return-on-Tangible-Equity Related Terms
Haw Par Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Haw Par's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Haw Par's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.79% mean?
Haw Par (HAWPF) has a Return-on-Tangible-Equity of 5.79% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Haw Par and its competitors. This is near median its historical median of 5.58. Over the past decade, Haw Par's Return-on-Tangible-Equity has ranged from 3.63 to 6.38. According to the industry distribution chart, Haw Par ranks #489 out of 895 companies in the Drug Manufacturers industry, placing it in the top 54.6%.
Is Haw Par's Return-on-Tangible-Equity too high?
Haw Par's current Return-on-Tangible-Equity of 5.79% is near median its 10-year median of 5.58. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 6.38. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Haw Par's value of 5.79% is 26.6% below this industry median. Based on the distribution chart, Haw Par ranks #489 out of 895 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Haw Par has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #489 out of 895 companies for Return-on-Tangible-Equity. This places Haw Par in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Haw Par's value of 5.79% is 26.6% below this benchmark. Historically, Haw Par's own Return-on-Tangible-Equity has ranged from 3.63 to 6.38 over the past decade. While the company's 10-year median is 5.58 vs. the industry median of 7.89, Haw Par has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Return-on-Tangible-Equity of 5.79% is 26.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Return-on-Tangible-Equity is 5.79%, which is near median its own 10-year median of 5.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Return-on-Tangible-Equity of 5.79%. The stock's GF Value™ is $8.90, compared to a current price of $12.00 — trading 34.8% above its estimated fair value. The current Return-on-Tangible-Equity is 5.79%, which is near median its 10-year median of 5.58 and 26.6% below the Drug Manufacturers industry median of 7.89. Haw Par's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Haw Par (HAWPF), the current Return-on-Tangible-Equity is 5.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.8% above its estimated GF Value™ of $8.90.
Key valuation signals for HAWPF:
Return-on-Tangible-Equity: 5.79% (near median its 10-year median of 5.58)
GF Value™: $8.90 vs. price of $12.00 (34.8% above fair value)
Industry Position: 26.6% below the Drug Manufacturers median (#489 of 895)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
96GF Score
Get the complete analysis for HAWPF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
